查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1968531

生物可吸收冠狀動脈支架市場－全球產業規模、佔有率、趨勢、機會、預測：按品牌、最終用戶、地區和競爭對手分類，2021-2031年

Bioresorbable Coronary Stents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Brand, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球生物可吸收冠狀動脈支架市場預計將從 2025 年的 5.5209 億美元成長到 2031 年的 9.9147 億美元，複合年成長率達到 10.25%。

這些裝置可作為臨時支架，疏通阻塞的動脈，恢復血流，然後逐漸溶解，從而有效避免植入永久性金屬植入。市場成長的主要促進因素是全球冠狀動脈疾病發生率的上升，以及臨床上對微創手術（支持血管自然修復）的偏好轉變。此外，降低永久性金屬支架相關的長期血栓形成風險的潛力，也促使介入心臟科醫師採用這些裝置，以期改善患者的治療效果。

市場概覽
預測期 2027-2031
市場規模：2025年 5.5209億美元
市場規模：2031年 9.9147億美元
複合年成長率：2026-2031年 10.25%
成長最快的細分市場 醫院和診所
最大的市場 北美洲

然而，阻礙市場快速成長的主要障礙在於，需要嚴格的長期臨床數據來檢驗其安全性與標準藥物釋放型支架相當。這給獲得監管部門核准帶來了重大挑戰。這種嚴格的審查迫使製造商投入大量資金進行漫長的臨床試驗，導致商業化進程的延遲。根據歐洲心臟學會的預測，到2024年，高所得成員國的經皮冠狀動脈介入治療率預計將達到每百萬人2330例，這凸顯了龐大的手術量，也顯示儘管面臨這些監管挑戰，支架技術仍需要不斷創新。

市場促進因素

全球心血管疾病盛行率的不斷上升是推動生物可吸收冠狀動脈支架全球市場發展的主要因素，也使得日益成長的患者群體迫切需要先進的治療方案。由於冠狀動脈疾病仍然是重要的全球健康問題，因此，人們越來越需要能夠恢復血管功能而無需留下永久性植入的治療方法。根據美國心臟協會（AHA）於2025年1月發布的《2025年心血管和中風統計更新》，2021年全球約有1,941萬人死於心血管疾病。生活方式相關的危險因子進一步加劇了這種死亡負擔。世界心臟聯盟於2025年5月發布的《2025年世界心臟報告》指出，高體重指數（BMI）每年導致190萬人死於心血管疾病，凸顯了冠狀動脈技術進步的關鍵性。

生物可吸收材料技術的進步正透過解決傳統支架的安全局限性，進一步推動市場發展。製造商正積極研發新一代支架，這些支架具有更細的支撐桿和更強的機械性能，可在血管恢復自然功能期間提供臨時支撐。近期的一些成功案例也印證了這項進展。例如，Elixir Medical公司於2025年5月在EuroPCR會議上公佈的「BIOADAPTOR隨機對照試驗」顯示，DynamX冠狀動脈生物適配器顯著降低了3年目標病變失敗率，從標準藥物釋放型支架的7.2%降至2.7%。這些數據對於恢復醫生信心和促進自適應冠狀動脈技術的廣泛應用至關重要。

市場挑戰

對長期臨床數據的嚴格要求是全球生物可吸收冠狀動脈支架市場成長的主要障礙。監管機構制定了高標準的證據要求，以確保這些臨時支架的安全性與已上市的藥物釋放型支架相當，尤其是在溶解階段血栓症等風險方面。這項要求迫使製造商在核准前進行長達數年的臨床試驗，顯著增加了研發成本並延長了開發週期。因此，這種延長的週期造成了不確定性，阻礙了快速投資，並妨礙了這些創新器械迅速進入市場，挑戰永久性金屬植入的主導地位。

監管瓶頸直接限制了市場利用冠狀動脈介入治療高需求的能力。儘管心臟病負擔沉重，但緩慢的產品核可限制了介入心臟科醫生可選擇的生物可吸收材料。根據歐洲心臟學會2024年報告，心血管疾病每年在成員國造成超過300萬人死亡，清楚顯示有大量患者需要有效的治療。然而，由於製造商獲取必要的安全數據需要耗費大量時間，市場滲透率不足，這實際上抑制了預期中從如此龐大的手術量中獲得的收入成長。

市場趨勢

從聚合物支架轉向鎂基金屬支架，標誌著支架技術的重大革新，旨在克服早期聚左旋乳酸）支架的機械性能缺陷和吸收時間過長等問題。與聚合物不同，鎂合金具有更優異的抗輻射強度，能夠製造出更細的支架梁。這顯著提高了支架的可靠性，同時減輕了血管壁的發炎負荷。這種材料的轉變解決了安全隱患，確保支架在血管癒合後能夠完全吸收，從而預防晚期血栓症。根據百奧特倫公司（Biotronic）2024年2月發布的關於FreeSolve支架獲得CE認證的新聞稿，BIOMAG-I試驗取得了卓越的成果，植入12個月後，99.3%的鎂支架梁分解，證實了這些金屬支架平台在快速恢復血管舒縮功能方面的有效性。

由於生物可吸收支架對尺寸誤差的接受度低於永久性金屬支架，因此引入先進的影像技術進行精準支架植入已成為最佳化其植入的關鍵標準。介入性心臟病專家正擴大使用光同調斷層掃瞄（OCT）來確保支架充分擴張並與血管壁緊密貼合，從而最大限度地降低機械故障和急性血管回縮的風險。統計學研究已證實，整合這種影像導引技術能夠提高臨床安全性。如同歐洲心臟學會2024年9月發布的新聞稿所述，與標準血管造影術相比，在光同調斷層掃瞄引導下接受治療的患者發生心因性死亡、支架血栓症和再次血管重建的風險降低了38%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：生物可吸收冠狀動脈支架的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按品牌（Magmaris、Magnitude、Meres-100、Desolve、其他）
    • 依最終使用者（醫院/診所、門診中心、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美生物可吸收冠狀動脈支架市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲生物可吸收冠狀動脈支架市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區生物可吸收冠狀動脈支架市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲生物可吸收冠狀動脈支架市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲生物可吸收冠狀動脈支架市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球生物可吸收冠狀動脈支架市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • BIOTRONIK SE & Co. KG
  • Meril Life Sciences Pvt. Ltd
  • Elixir Medical Corporation.
  • Reva Medical, LLC
  • Terumo Corporation
  • Lepu Medical Technology（Beijing）Co.,Ltd
  • MicroPort Scientific Corporation
  • LifeTech Scientific Corporation
  • Boston Scientific Corporation
  • Medtronic plc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16356

The Global Bioresorbable Coronary Stents Market is projected to expand from USD 552.09 Million in 2025 to USD 991.47 Million by 2031, achieving a CAGR of 10.25%. These devices function as transient scaffolds that open obstructed arteries to restore blood flow before gradually dissolving, effectively eliminating the need for permanent metallic implants. The market's growth is primarily driven by the rising global incidence of coronary artery disease and a shift in clinical preference toward minimally invasive procedures that support natural vessel restoration. Furthermore, the potential to mitigate long-term thrombotic risks associated with permanent metal stents is encouraging adoption among interventional cardiologists aiming to enhance patient outcomes.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 552.09 Million
Market Size 2031USD 991.47 Million
CAGR 2026-203110.25%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

However, a major obstacle hindering rapid market growth is the stringent requirement for extensive long-term clinical data to verify safety profiles equivalent to standard drug-eluting stents, which creates a significant barrier to regulatory approval. This intense scrutiny compels manufacturers to invest in prolonged trials, thereby delaying commercialization. According to the European Society of Cardiology, high-income member nations reported a percutaneous coronary intervention rate of 2,330 per million people in 2024, highlighting the substantial procedural volume that demands continuous innovation in stent technology despite these regulatory challenges.

Market Driver

The escalating global prevalence of cardiovascular diseases serves as the primary engine for the Global Bioresorbable Coronary Stents Market, creating an urgent need for advanced therapeutic solutions for a growing patient population. As coronary artery disease remains a critical global health burden, there is an intensifying demand for interventions that can restore vessel physiology without leaving permanent implants. According to the American Heart Association's '2025 Heart Disease and Stroke Statistics Update' from January 2025, cardiovascular disease caused approximately 19.41 million global deaths in 2021. This mortality burden is exacerbated by lifestyle-related risk factors; the World Heart Federation's 'World Heart Report 2025' from May 2025 notes that high body mass index contributed to 1.9 million annual cardiovascular deaths, underscoring the critical need for evolving coronary technologies.

Technological advancements in bioresorbable material science are further propelling the market by resolving the safety limitations of earlier scaffold generations. Manufacturers are aggressively developing next-generation devices with thinner struts and enhanced mechanical properties to provide temporary support before allowing the vessel to resume natural function. This progress is validated by recent successes, such as Elixir Medical's May 2025 presentation at EuroPCR regarding the 'BIOADAPTOR Randomized Controlled Trial,' where the DynamX coronary bioadaptor showed a statistically significant reduction in target lesion failure rates to 2.7% at three years compared to 7.2% for standard drug-eluting stents. Such data is pivotal in restoring physician confidence and fostering the adoption of adaptive coronary technologies.

Market Challenge

The stringent requirement for rigorous long-term clinical data poses a significant barrier to the growth of the Global Bioresorbable Coronary Stents Market. Regulatory bodies enforce high evidentiary standards to ensure that these transient scaffolds maintain safety profiles comparable to established drug-eluting stents, particularly regarding risks such as thrombosis during the dissolution phase. This necessity forces manufacturers to commit to multi-year clinical trials before gaining approval, drastically inflating research costs and extending development timelines. Consequently, this prolonged cycle generates uncertainty and discourages rapid investment, preventing these innovative devices from quickly entering the market to challenge the dominance of permanent metallic implants.

This regulatory bottleneck directly limits the market's capacity to capitalize on the high demand for coronary interventions. Although the burden of heart disease is immense, the slow pace of product validation restricts the availability of bioresorbable options for interventional cardiologists. As reported by the European Society of Cardiology in 2024, cardiovascular disease causes over 3 million deaths annually across its member countries, highlighting the massive patient population requiring effective treatment. However, because manufacturers are impeded by the time-intensive process of generating required safety data, the market remains underpenetrated, and potential revenue growth from this high procedural volume is effectively stalled.

Market Trends

The transition from polymer-based to magnesium-based metallic scaffolds represents a critical evolution aimed at overcoming the mechanical inferiority and prolonged resorption times of early poly-L-lactic acid devices. Unlike polymers, magnesium alloys provide superior radial strength and allow for thinner struts, significantly improving deliverability while reducing the inflammatory burden on vessel walls. This shift in materials addresses safety concerns by ensuring the scaffold disappears once the vessel heals, thereby preventing late-stage thrombosis. According to Biotronik's February 2024 press release regarding CE-approval for the Freesolve scaffold, the BIOMAG-I trial demonstrated an exceptional 99.3% magnesium strut degradation 12 months after implantation, confirming the viability of these metallic platforms to rapidly restore natural vasomotion.

The implementation of advanced imaging for precision scaffold placement is emerging as a mandatory standard to optimize the implantation of bioresorbable devices, which are less forgiving of sizing errors than permanent metallic stents. Interventional cardiologists are increasingly utilizing optical coherence tomography to ensure proper scaffold expansion and apposition, minimizing the risk of mechanical failure or acute vessel recoil. This integration of imaging guidance is statistically proven to enhance clinical safety; as noted by the European Society of Cardiology in a September 2024 press release, patients treated with optical coherence tomography guidance experienced a 38% reduction in the combined risk of cardiac death, stent thrombosis, and revascularization compared to standard angiography.

Key Market Players

  • BIOTRONIK SE & Co. KG
  • Meril Life Sciences Pvt. Ltd
  • Elixir Medical Corporation.
  • Reva Medical, LLC
  • Terumo Corporation
  • Lepu Medical Technology (Beijing)Co.,Ltd
  • MicroPort Scientific Corporation
  • LifeTech Scientific Corporation
  • Boston Scientific Corporation
  • Medtronic plc

Report Scope

In this report, the Global Bioresorbable Coronary Stents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bioresorbable Coronary Stents Market, By Brand

  • Magmaris
  • Magnitude
  • MeRes-100
  • DESolve
  • Others

Bioresorbable Coronary Stents Market, By End User

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Bioresorbable Coronary Stents Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bioresorbable Coronary Stents Market.

Available Customizations:

Global Bioresorbable Coronary Stents Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bioresorbable Coronary Stents Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Brand (Magmaris, Magnitude, MeRes-100, DESolve, Others)
    • 5.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Bioresorbable Coronary Stents Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Brand
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bioresorbable Coronary Stents Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Brand
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Bioresorbable Coronary Stents Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Brand
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Bioresorbable Coronary Stents Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Brand
        • 6.3.3.2.2. By End User

7. Europe Bioresorbable Coronary Stents Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Brand
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Bioresorbable Coronary Stents Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Brand
        • 7.3.1.2.2. By End User
    • 7.3.2. France Bioresorbable Coronary Stents Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Brand
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Bioresorbable Coronary Stents Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Brand
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Bioresorbable Coronary Stents Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Brand
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Bioresorbable Coronary Stents Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Brand
        • 7.3.5.2.2. By End User

8. Asia Pacific Bioresorbable Coronary Stents Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Brand
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Bioresorbable Coronary Stents Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Brand
        • 8.3.1.2.2. By End User
    • 8.3.2. India Bioresorbable Coronary Stents Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Brand
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Bioresorbable Coronary Stents Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Brand
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Bioresorbable Coronary Stents Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Brand
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Bioresorbable Coronary Stents Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Brand
        • 8.3.5.2.2. By End User

9. Middle East & Africa Bioresorbable Coronary Stents Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Brand
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Bioresorbable Coronary Stents Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Brand
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Bioresorbable Coronary Stents Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Brand
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Bioresorbable Coronary Stents Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Brand
        • 9.3.3.2.2. By End User

10. South America Bioresorbable Coronary Stents Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Brand
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Bioresorbable Coronary Stents Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Brand
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Bioresorbable Coronary Stents Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Brand
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Bioresorbable Coronary Stents Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Brand
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Bioresorbable Coronary Stents Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. BIOTRONIK SE & Co. KG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Meril Life Sciences Pvt. Ltd
  • 15.3. Elixir Medical Corporation.
  • 15.4. Reva Medical, LLC
  • 15.5. Terumo Corporation
  • 15.6. Lepu Medical Technology (Beijing)Co.,Ltd
  • 15.7. MicroPort Scientific Corporation
  • 15.8. LifeTech Scientific Corporation
  • 15.9. Boston Scientific Corporation
  • 15.10. Medtronic plc

16. Strategic Recommendations

17. About Us & Disclaimer